212 related articles for article (PubMed ID: 31074248)
1. The influence of BRCA variants of unknown significance on cancer risk management decision-making.
Chern JY; Lee SS; Frey MK; Lee J; Blank SV
J Gynecol Oncol; 2019 Jul; 30(4):e60. PubMed ID: 31074248
[TBL] [Abstract][Full Text] [Related]
2. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
[TBL] [Abstract][Full Text] [Related]
3. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
4. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.
Culver JO; Brinkerhoff CD; Clague J; Yang K; Singh KE; Sand SR; Weitzel JN
Clin Genet; 2013 Nov; 84(5):464-72. PubMed ID: 23323793
[TBL] [Abstract][Full Text] [Related]
5. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.
Murray ML; Cerrato F; Bennett RL; Jarvik GP
Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163
[TBL] [Abstract][Full Text] [Related]
6. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
[TBL] [Abstract][Full Text] [Related]
7. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
8. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
9. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Guidozzi F
Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
[TBL] [Abstract][Full Text] [Related]
10. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
11. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
12. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
13. Risk-reducing salpingo-oophorectomy among diverse patients with
Lamacki AJ; Spychalska S; Maga T; Balay L; Lugo Santiago N; Hoskins K; Richardson K; Class QA; MacLaughlan David S
BMJ Open; 2024 Jun; 14(6):e082608. PubMed ID: 38889943
[TBL] [Abstract][Full Text] [Related]
14. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.
Richter S; Haroun I; Graham TC; Eisen A; Kiss A; Warner E
Ann Oncol; 2013 Nov; 24 Suppl 8():viii69-viii74. PubMed ID: 24131974
[TBL] [Abstract][Full Text] [Related]
15. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
16. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
17. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
Hull LE; Haas JS; Simon SR
Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
[TBL] [Abstract][Full Text] [Related]
20. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]